Greenwich Lifesciences Company Top Insiders
GLSI Stock | USD 13.40 0.19 1.44% |
Greenwich Lifesciences' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Greenwich Lifesciences suggests that almost all insiders are extremely bullish. Greenwich Lifesciences employs about 3 people. The company is managed by 5 executives with a total tenure of roughly 7 years, averaging almost 1.0 years of service per executive, having 0.6 employees per reported executive.
Greenwich Lifesciences' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2024-11-21 | Jaye Thompson | Acquired 1000 @ 12.91 | View | ||
2024-09-26 | Snehal Patel | Acquired 1500 @ 14.63 | View | ||
2024-08-12 | Jaye Thompson | Acquired 800 @ 13.85 | View | ||
2024-08-05 | Snehal Patel | Acquired 5500 @ 13.18 | View | ||
2024-08-02 | Jaye Thompson | Acquired 1000 @ 15.15 | View | ||
2024-07-23 | Snehal Patel | Acquired 1500 @ 15.89 | View | ||
2024-07-18 | Jaye Thompson | Acquired 1000 @ 16 | View | ||
2024-06-13 | Snehal Patel | Acquired 174825 @ 14.3 | View | ||
2024-04-01 | Snehal Patel | Acquired 3000 @ 19.08 | View | ||
2024-03-22 | Snehal Patel | Acquired 2500 @ 19.98 | View | ||
2024-03-20 | Snehal Patel | Acquired 1500 @ 17.68 | View | ||
2024-03-04 | Snehal Patel | Acquired 4100 @ 13.03 | View | ||
2024-02-15 | Snehal Patel | Acquired 12700 @ 11.07 | View |
Monitoring Greenwich Lifesciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Greenwich |
Greenwich Lifesciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.7245) % which means that it has lost $0.7245 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2367) %, meaning that it created substantial loss on money invested by shareholders. Greenwich Lifesciences' management efficiency ratios could be used to measure how well Greenwich Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.34. The Greenwich Lifesciences' current Return On Capital Employed is estimated to increase to -1.32. As of now, Greenwich Lifesciences' Net Tangible Assets are increasing as compared to previous years. Other Assets is expected to grow at the current pace this year, while Total Assets are projected to decrease to under 6.6 M.The Greenwich Lifesciences' current Common Stock Shares Outstanding is estimated to increase to about 13.8 M, while Net Loss is projected to decrease to (4.3 M).
Greenwich Lifesciences Workforce Comparison
Greenwich Lifesciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,124. Greenwich Lifesciences adds roughly 3.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Greenwich Lifesciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Greenwich Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Greenwich Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Greenwich Lifesciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2021-12-01 | 3.0 | 3 | 1 | 3,151 | 0.00 |
2020-12-01 | 6.0 | 6 | 1 | 8,500 | 187,266 |
2020-09-01 | 1.1481 | 31 | 27 | 2,350,893 | 1,948,503 |
Greenwich Lifesciences Notable Stakeholders
A Greenwich Lifesciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Greenwich Lifesciences often face trade-offs trying to please all of them. Greenwich Lifesciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Greenwich Lifesciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Christine Fischette | VP Development | Profile | |
Snehal Patel | CFO CEO | Profile | |
Eric Rothe | Founder Director | Profile | |
Frank MD | Chief Director | Profile | |
Jaye Thompson | Vice Affairs | Profile |
About Greenwich Lifesciences Management Performance
The success or failure of an entity such as Greenwich Lifesciences often depends on how effective the management is. Greenwich Lifesciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Greenwich management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Greenwich management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (1.27) | (1.34) | |
Return On Capital Employed | (1.39) | (1.32) | |
Return On Assets | (1.27) | (1.33) | |
Return On Equity | (1.33) | (1.26) |
Greenwich Lifesciences Workforce Analysis
Traditionally, organizations such as Greenwich Lifesciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Greenwich Lifesciences within its industry.Greenwich Lifesciences Manpower Efficiency
Return on Greenwich Lifesciences Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 3M | |
Net Loss Per Executive | 1.8M | |
Working Capital Per Employee | 2.2M | |
Working Capital Per Executive | 1.3M |
Complementary Tools for Greenwich Stock analysis
When running Greenwich Lifesciences' price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |